Epidermal growth factor receptor (EGFR) is an anticancer drug target for a number of
cancers, such as non-small cell lung cancer. However, unsatisfying treatment effects, terrible …

Purpose Neuroendocrine neoplasms can occur as part of inherited disorders, usually in the
form of well-differentiated, slow-growing tumors (NET). The main predisposing syndromes …

Medullary thyroid carcinoma (MTC) is a rare neuroendocrine malignancy derived from
parafollicular cells (C cells) of the thyroid. Here we presented a comprehensive multi-omics …

Background Patients with neuroendocrine tumours (NETs) need alternative therapies after
failure of first-line therapy. Patients and methods This phase II trial evaluated lurbinectedin, a …

Somatostatin, a somatotropin release inhibiting factor (SST, SRIF), is a widely distributed
multifunctional cyclic peptide and acts through a transmembrane G protein-coupled receptor …

Somatostatin (SST)/somatotropin release-inhibiting factor (SRIF) is a well-known
neuropeptide, widely distributed in the central and peripheral nervous systems, that …

Simple Summary Neuroendocrine tumors (NETs) have become increasingly common. There
are several effective treatment options for advanced NETs. However, there are limited …

Pancreatic cancer (PC), a disease with high heterogeneity and a dense stromal
microenvironment, presents significant challenges and a bleak prognosis. Recent …

Objective Metabolic profiling is a valuable tool to characterize tumor biology but remains
largely unexplored in neuroendocrine tumors (NETs). Our aim was to comprehensively …

Background Neuroendocrine carcinoma (NEC) is a rare and highly malignant variation of
prostate adenocarcinoma. We aimed to investigate the prognostic value of NEC in prostate …